On Consensus and Funding

A few days ago I picked up a copy of Time magazine, which featured several of the most prominent scientists of this century. One of the most prominent was, of course, Albert Einstein. Then later, I read the Opinion page by Nejat Düzgünes in the April 12 issue of The Scientist.1 The juxtaposition of these two articles got me thinking: What would have happened if Albert Einstein had been required to submit to a funding agency in Switzerland a grant proposal to study relativity but under

Written byRoger Floyd
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

A few days ago I picked up a copy of Time magazine, which featured several of the most prominent scientists of this century. One of the most prominent was, of course, Albert Einstein. Then later, I read the Opinion page by Nejat Düzgünes in the April 12 issue of The Scientist.1 The juxtaposition of these two articles got me thinking: What would have happened if Albert Einstein had been required to submit to a funding agency in Switzerland a grant proposal to study relativity but under the same requirements and documentation of funding agencies today? He wouldn't have stood a chance of being funded.

Consider:

But there is more to the granting agencies than the narrowness of view, or the other requirements that Dr. Einstein could not meet. For example, I once submitted a grant proposal to a federal agency to study the effects of nitric oxide on a particular ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies